MIT engineers have developed a “vessel-on-a-chip” platform that uses magnetic mechanical stretching to guide the growth of blood vessels in engineered tissues. According to research published in the Proceedings of the National Academy of Sciences, applying controlled strain to lab-grown vessels increases capillary sprouting and allows researchers to program the direction of growth, potentially solving a long-standing challenge in creating viable, implantable artificial tissues.
Overcoming the Vascularization Barrier in Tissue Engineering
Engineered tissues—such as lab-grown skin, liver, or muscle—frequently fail because they lack the complex vascular networks required to transport oxygen and nutrients to deep cell layers. Without a dense network of blood vessels, these tissues cannot survive or function once implanted. Current bioprinting methods often struggle to reproduce the fine, capillary-scale architecture found in human biology.
Ritu Raman, an associate professor of mechanical engineering at MIT and co-lead author of the study, notes that the ability to program vessel growth using physical cues is essential for the scalable fabrication of tissues intended to restore function after injury. By moving away from purely chemical signaling, the team has found a way to use mechanical force to dictate the architecture of synthetic vascular systems.
Did you know?
The MIT research team found that 5 percent dynamic strain was the most effective level for producing the highest number of new capillary sprouts. When they increased the strain to 15 percent, the vessels grew longer but fewer in number.
How Mechanical Stretching Guides Vessel Growth
The MIT vessel-on-a-chip device is smaller than a postage stamp and features a central channel lined with human endothelial cells. Inside the surrounding collagen gel, a small magnetic actuator is embedded. A motorized three-axis system controls an external magnet, which pulls on the actuator to stretch the vessel wall at precise frequencies and intensities.
The researchers observed that the direction of the mechanical stretch acts as a “compass” for growing vessels. When the gel was stretched along a specific axis, sprouts preferentially extended in that same direction. By changing the direction of the magnetic pull—for instance, shifting from an x-axis to a y-axis—the team successfully reoriented growing sprouts into L-shaped configurations. Approximately 67 percent of sprouts reoriented during x-to-y stimulation, and 71 percent followed when shifted along the z-axis.
The Role of PIEZO1 in Mechanotransduction
The study identified the gene PIEZO1 as a primary driver of how cells “feel” and respond to mechanical forces. PIEZO1 encodes a pressure-sensitive ion channel in the cell membrane that opens when the cell is stretched, triggering a cascade of biological changes.
When the team suppressed PIEZO1 using gene editing, the increase in vessel sprouting caused by dynamic strain dropped from 1.6-fold to 1.1-fold. This confirms that the channel is a critical component of the cell’s mechanical sensing apparatus. Interestingly, barrier strengthening—the process by which the vessel becomes less permeable—remained effective even when PIEZO1 was suppressed, suggesting that other, as-yet-unidentified pathways are responsible for reinforcing the vessel walls.
Pro Tip:
If you are interested in the intersection of bioengineering and mechanical systems, keep an eye on developments in “organ-on-a-chip” technology.
Future Implications for Regenerative Medicine
While the current model is limited to endothelial cells, the researchers plan to incorporate additional cell types, such as smooth muscle cells and fibroblasts, to better mimic the complexity of native human circulation. The ultimate goal is to apply these mechanical patterning techniques to thicker, more functional engineered muscle implants.
By providing a way to guide vessel growth through physical instructions, this magnetic platform may reduce reliance on chemical gradients, which are harder to control in large-scale tissue manufacturing. As the technology matures, it could lead to more realistic laboratory models for studying vascular diseases and more effective surgical interventions for patients with debilitating tissue injuries.
Frequently Asked Questions
Why can’t engineered tissues just grow their own blood vessels?
While cells can self-organize, they often fail to form the dense, organized, and hollow networks necessary to sustain life in thick tissues. Without external cues, these networks are often disorganized or inefficient.
What is the benefit of the magnetic actuation system?
The system allows researchers to adjust the strength, frequency, and direction of mechanical strain in real-time. This provides precise, programmable control over vessel geometry that traditional bioprinting cannot achieve.
Is this technology ready for human implants?
Not yet. The current model is a laboratory platform designed to test the feasibility of mechanical guidance. Future work must integrate continuous blood flow and diverse cell types before clinical applications can be considered.
Are you fascinated by the future of synthetic biology and tissue engineering? Subscribe to our newsletter for the latest updates on medical technology breakthroughs or leave a comment below to join the discussion on the future of regenerative medicine.
Keep reading
- Did Venus Swallow Its Moon?
- Warhammer 40,000: Dawn of War IV Battle Report Features Orks vs. Necrons
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)